ClinicalTrials.gg
RecruitingNCT06572046Updated Mar 27, 2026

STOP-HSP.Net: a Registry for Hereditary Spastic Paraplegia as an Integration Tool for Future Therapeutic Strategies

An observational study in Hereditary Spastic Paraplegia, sponsored by IRCCS Fondazione Stella Maris. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by IRCCS Fondazione Stella Maris · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
500
Sex
All
01

Study summary

Our goal is to create a solid and harmonious disease registry of patient affected by hereditary spastic paraplegia (HSP) that facilitates the collection and management of patients' data over time encouraging the research and the development of future clinical trials. In-depth clinical phenotyping will develop significant clinical outcome measures that can be used in clinical trials and will allow the phenotypic complexity of the disease to be captured with the use of validated clinical scales, biomarkers and so-called patient reported outcomes (PROs).

Read the detailed description

The registry will involve five recruiting clinical centres (IRCCS Fondazione Stella Maris in Pisa, IRCCS Eugenio Medea in Conegliano, IRCCS Policlinico Gemelli in Rome, IRCCS Istituto di Scienze Neurologiche in Bologna, Università degli studi di Messina) and a data analysis partner (CINECA).

Participants will be assessed annually at one of the five participating clinical sites. For each patient, at least one follow-up visit will be scheduled at an interval of 12 months in order to monitor and compare the longitudinal progression of HSP in similar groups (for example based on phenotype, age at onset, or genotype). At each visit all enrolled subjects will carry out a clinical-instrumental evaluation as per clinical practice, including: anamnestic collection, general and neurological objective examination; administration of illness scales (e.g. the SPRS scale) and quality of life questionnaires. Any biological samples will be collected as tissues, blood or urine and stored in the laboratories or bio-repositories of the individual centers and also reported in the electronic clinical report form (CRF) of STOP-HSP.net. The results of further diagnostic tests carried out such as Optical coherence tomography (OCT), brain magnetic resonance imaging (MRI) or neurophysiology performed during diagnostic practice or clinical follow up will also be collected. Any further clinical scales/evaluation questionnaires to be administered will be selected according to clinical need based on the neurological characteristics and genotype of each participant. All data relating to further instrumental and/or neurophysiological investigations carried out by the patient for clinical needs will also be collected.

The data collected during the aforementioned clinical-instrumental-laboratory evaluations will be entered into the STOP-HSP.net register in pseudonymized form.

02

Conditions studied

  • Hereditary Spastic Paraplegia
03

In context

Spastic Paraplegia, Hereditary

51 studies on the registry are indexed under Spastic Paraplegia, Hereditary; 20 are open to participants now.

This study's planned enrollment of 500 is above the median of 100 across 25 observational studies indexed under Spastic Paraplegia, Hereditary.

Browse Spastic Paraplegia, Hereditary studies →

Lead sponsor

IRCCS Fondazione Stella Maris is the lead sponsor of 46 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects affected by HSP both with a known genetic diagnosis and in the absence of genotypic characterization

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • clinical diagnosis of pure or complex HSP/spastic ataxia, even in the absence of a known genetic diagnosis
  • participants/parents/legal guardians will have to give for enrollment in the registry and privacy data management

Exclusion criteria

Exclusion Criteria:

  • subjects affected by secondary forms of HSP
  • presenting comorbidities that affect the general clinical picture according to clinical judgment
  • lack of
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
500 participants (estimated)
Target follow-up
15 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Establishment of the STOP-HSP.net disease registry to systematically document the clinical presentation and natural history of patients affected by both pediatric-onset and adult-onset HSP

    Time frame: five years

  2. Definition of genotype-specific disease progression measured by evaluating the scores of the clinical scale "Spastic Paraplegia Rating Scale" (SPRS)

    Spastic Paraplegia Rating Scale (SPRS) is a 13-item scale designed to rate motor impairment in pure or complex forms of spastic paraplegia. Its score varies from 0 to 52, whereas higher scores indicate greater motor impairment.

    Time frame: five years

  3. Identification of new genetic forms of HSP through the use of Whole Genome Sequencing (WGS) in selected familial cases

    Time frame: five years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data collected during the clinical-instrumental-laboratory evaluations will be entered into the STOP-HSP.net register in pseudonymized form. Each patient will be identified by a progressive code of the electronic CRF together with a unique alphanumeric identification code (automatically generated). This identification code will be used by the Center in place of the relevant name in each communication of the linked data. The Recruiting Center will be the only and exclusive entity able to associate the identification code with the personal data. The data collected in the STOP-HSP.net register will be stored on the Cloud HPC virtual infrastructure provided by CINECA on Italian territory in pseudonymized form.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 26, 2024
StartActual
Jan 24, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06572046
Lead sponsor
IRCCS Fondazione Stella Maris
Collaborators
IRCCS Eugenio Medea, Università degli studi di Messina, IRCCS Istituto delle Scienze Neurologiche di Bologna, Catholic University of the Sacred Heart, CINECA, Fondazione Telethon
Responsible party
Filippo Maria Santorelli (Director of Molecular Medicine, IRCCS Fondazione Stella Maris) — Principal investigator
First posted
Aug 26, 2024
Start date
Jan 24, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Mar 27, 2026

Study contacts

Filippo M Santorelli, Dr.
Contact
filippo.santorelli@fsm.unipi.it
+39 050886275
Sara Satolli, Dr.
Contact
sara.satolli@fsm.unipi.it
Filippo M Santorelli, Dr.
principal investigator · IRCCS Fondazione Stella Maris

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion